APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Trial Profile

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2018

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2018 According to a company media release, Alnylam Pharmaceuticals plans to present data from this trial in early, mid-, and late 2018.
    • 18 Dec 2017 According to a Sanofi Genzyme media release, Sanofi Genzyme and Alnylam Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for patisiran for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
    • 12 Dec 2017 According to an Alnylam Pharmaceuticals media release, company has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for patisiran for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) and has requested priority review for the application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top